tradingkey.logo

Edap Tms SA

EDAP

2.500USD

+0.160+6.84%
Close 09/19, 16:00ETQuotes delayed by 15 min
93.48MMarket Cap
LossP/E TTM

Edap Tms SA

2.500

+0.160+6.84%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
99 / 207
Overall Ranking
215 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Hold
Current Rating
5.767
Target Price
+146.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.26% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 61.93M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 570.27.
Fairly Valued
The company’s latest PE is -4.34, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.58M shares, decreasing 12.61% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.37.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.69, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 13.61M, representing a year-over-year decrease of 7.65%, while its net profit experienced a year-over-year decrease of 16.99%.

Score

Industry at a Glance

Previous score
6.69
Change
0

Financials

6.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.21

Operational Efficiency

6.45

Growth Potential

5.78

Shareholder Returns

7.09

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Healthcare Equipment & Supplies industry's average of 3.59. Its current P/E ratio is -4.06, which is -29.49% below the recent high of -2.86 and -7.20% above the recent low of -4.35.

Score

Industry at a Glance

Previous score
2.80
Change
1.2

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 99/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.67, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Edap Tms SA is 1.80, with a high of 14.00 and a low of 1.50.

Score

Industry at a Glance

Previous score
6.67
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts
Hold
Current Rating
5.767
Target Price
+146.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Edap Tms SA
EDAP
3
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.71, which is higher than the Healthcare Equipment & Supplies industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.16 and the support level at 1.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
8.71
Change
0.17

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.067
Neutral
RSI(14)
62.261
Neutral
STOCH(KDJ)(9,3,3)
35.054
Neutral
ATR(14)
0.291
Low Volatility
CCI(14)
-31.851
Neutral
Williams %R
66.409
Sell
TRIX(12,20)
2.263
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
2.396
Buy
MA10
2.524
Sell
MA20
2.284
Buy
MA50
1.757
Buy
MA100
1.796
Buy
MA200
2.003
Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 41.67%, representing a quarter-over-quarter increase of 0.71%. The largest institutional shareholder is CI Select Canadian Equity Fund, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Soleus Capital Management, L.P.
7.31M
--
Morgan Stanley & Co. International Plc
3.36M
-0.09%
Rock Springs Capital Management LP
1.27M
-20.22%
Bruce & Company, Inc.
553.65K
--
Apis Capital Advisors LLC
524.00K
+0.96%
UBS Financial Services, Inc.
38.46K
-14.82%
Schonfeld Strategic Advisors LLC
166.43K
+3.50%
Parkman Healthcare Partners LLC
154.83K
--
Cahill Financial Advisors, Inc.
134.96K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.18, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is -0.14. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.18
Change
0
Beta vs S&P 500 index
-0.14
VaR
+4.75%
240-Day Maximum Drawdown
+58.50%
240-Day Volatility
+97.96%
Return
Best Daily Return
60 days
+24.18%
120 days
+24.18%
5 years
+24.18%
Worst Daily Return
60 days
-8.36%
120 days
-18.52%
5 years
-26.94%
Sharpe Ratio
60 days
+1.76
120 days
+0.74
5 years
+0.10
Risk Assessment
Maximum Drawdown
240 days
+58.50%
3 years
+90.03%
5 years
+90.03%
Return-to-Drawdown Ratio
240 days
-0.19
3 years
-0.29
5 years
-0.10
Skewness
240 days
+0.95
3 years
+0.10
5 years
+0.36
Volatility
Realised Volatility
240 days
+97.96%
5 years
+74.80%
Standardised True Range
240 days
+7.28%
5 years
+14.49%
Downside Risk-Adjusted Return
120 days
+129.86%
240 days
+129.86%
Maximum Daily Upside Volatility
60 days
+94.95%
Maximum Daily Downside Volatility
60 days
+48.04%
Liquidity
Average Turnover Rate
60 days
+0.20%
120 days
+0.28%
5 years
--
Turnover Deviation
20 days
+37.47%
60 days
-22.19%
120 days
+10.63%

Peer Comparison

Healthcare Equipment & Supplies
Edap Tms SA
Edap Tms SA
EDAP
6.00 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
8.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI